Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II

NCT03717298 is registered in ClinicalTrials.gov with Catalysis SL as lead sponsor.

NCT NCT03717298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03717298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II
Lead sponsor
Catalysis SL
Phase
Phase 2
Overall status
Completed
Start date
October 30, 2018
Completion date
January 20, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, advanced cancer, digestive system diseases, digestive system neoplasms, endocrine gland neoplasms, endocrine system diseases, pancreatic cancer, pancreatic diseases, pancreatic neoplasms